Funding Opportunities in Cancer Research

 

research1  

For assistance with funding, contact: 
Paige Isom, Research Adminstrator,
Funding and Awards
Phone: 314-454-8980
E-mail:  isomp@wudosis.wustl.edu

 

 

FUNDING OPPORTUNITY SEARCH TOOLS 

Siteman Cancer Center — Internal

Barnes-Jewish Foundation
  

Deadline Funding Opportunity Sponsor Amount Description
May 1, 2015 Internal funding: SPORE in Leukemia Career Enhancement Awards/Development Research Awards WUSM Spore in Leukemia $60,000 per year for two years  CEP: The research initiatives that will be funded by the CEP are expected to have a major translational component, focusing on leukemia etiology, diagnosis, early detection, treatment, or population science.
DRP: The goal is to support innovative translational leukemia research. Proposed projects will be reviewed with the intent that they will develop sufficiently, within one-two years, to be submitted for external peer-reviewed funding. For projects with a clinical trial, they must be ready to study activation within six months of award.
May 1 and Oct. 1, 2015 Internal funding: Siteman Investment Program Siteman Cancer Center Varies from $200,000 to $800,000 over 2 years SCC will fund the following mechanisms: Pre-R01 for WUSTL Medical School Faculty, Pre-R01 for SLU Consortium Faculty and WUSTL Danforth Campus Faculty, Multi-PI Pre-R01 for all SCC members, Pre-SPORE/PPG Program for all SCC Members.
May 29, 2015 New: Reach Grant Alex's Lemonade Stand Up to $125,000 in total costs may be requested per year The purpose of the Reach Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. The goal of this award is to support selected “late translational” studies needed to ultimately initiate a clinical trial. Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.
June 1, 2015 Elsa U. Pardee Foundation Grant  Elsa U. Pardee Foundation $100,000 for one year This Foundation supports discovery of new approaches for cancer treatment and cure. Previous WU awardees: Albert Kim (2013); David Tran (2013); Joshua Hood (2009); Mai Xu (2009); Sheila Stewart (2007); Jason Weber (2005); Steven Weintraub (2005); Rebecca Aft (2003); Tim Fleming (2001)
Pre-Application: June 2, 2015 New: Lung Cancer Research Program - Clinical Exploration Award DOD  $450,000 over 3 years  This award mechanism supports early-phase, proof-of-principle clinical trials and correlative studies to investigate hypothesis-based, innovative interventions that have the potential to resolve current clinical barriers and result in a profound impact on the clinical management of lung cancer.
Pre-Application: June 2, 2015 New: Lung Cancer Research Program - Career Development Award DOD  $240,000 over 2 years The CDA supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery.
Pre-Application: June 2, 2015 New: Lung Cancer Research Program - Idea Development Award  DOD  $350,000 over 2 years This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.
June 5, 2015 New: Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01) NCI $450,000 over 3 years The purpose of this FOA is to invite applications for projects to expand and improve the utility of mouse cancer and tumor models for translational research.
June 19, 2015 New: Image-guided Drug Delivery in Cancer (R01) NIH/NCI Budget not limited; Project period up to 5 years This FOA will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.
June 29, 2015 New: Research Answers to NCI's Provocative Questions (R21) NCI R21: $275,000 over 2 years  These FOAs are designed to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
June 29, 2015 New: Research Answers to NCI's Provocative Questions (R01) NCI R01: Budgets not limited; Project period up to 5 years  These FOAs are designed to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
June 30, 2015 New: Bio-Therapeutics Impact Award Alex's Lemonade Stand Up to $1.5 million in total costs may be requested  The ALSF Bio-Therapeutics Impact award provides funding to support investigator-initiated clinical trials using biologic therapies, including but not limited to immunotherapy (including cell therapies), gene therapy and small molecules. This grant category was initiated to accelerate the development of clinical trials for promising biologic approaches to treat childhood cancers.